Carl Zeiss Meditec (OTCMKTS:CZMWY) Downgraded by Zacks Research to “Strong Sell”

Carl Zeiss Meditec (OTCMKTS:CZMWY) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports.

Separately, UBS Group lowered Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Carl Zeiss Meditec has an average rating of “Reduce”.

Carl Zeiss Meditec Stock Down 3.9%

Shares of OTCMKTS CZMWY opened at $34.41 on Tuesday. Carl Zeiss Meditec has a one year low of $26.65 and a one year high of $55.94. The business’s fifty day moving average price is $32.16 and its 200-day moving average price is $31.08.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.